Boehringer Ingelheim To Boost Cancer Immunology Portfolio with Novel Cancer Vaccines

 
• By Sten Stovall
  
Vial
AMAL’s KISIMA platform leverages peptide/protein-based vaccination technology • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business